AbbVie's Humira Patents Are Noninventive, Boehringer Says
Drugmaker Boehringer Ingelheim International GmbH on Monday shot back at competitor AbbVie Inc.'s suit in Delaware federal court alleging that its proposed biosimilar of the blockbuster immunosuppressant Humira runs afoul of...To view the full article, register now.
Already a subscriber? Click here to view full article